Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
GEOMETRY-N
Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC
- NCT04926831 ↗
- Terminated
- Novartis Pharmaceuticals
- Focused
We haven't built an HCP commentary report on GEOMETRY-N (capmatinib) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GEOMETRY-N so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N)
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- capmatinib
- Arms
- Cohort A (MET exon 14 skipping mutations) · Experimental
- Cohort B (high MET amplification) · Experimental
- Enrollment
- 4
- Primary outcomes
- Major Pathological Response (MPR) Rate
- Sponsor
- Novartis Pharmaceuticals
- Start
- Aug 10, 2022
- Primary completion
- Mar 13, 2024
- Results posted
- Yes
- Registry record
- NCT04926831 · updated Oct 16, 2025